Mineralocorticoid receptor antagonist use in eligible patients following acute myocardial infarction: Real world data from the Acute Coronary Syndrome Israeli Surveys: 2004–2010

Clinical impact of mineralocorticoid receptor antagonists treatment after acute coronary syndrome in the real world: A propensity score matching analysis

“…Our results are similar to those obtained in large registries with only one in seven eligible patients prescribed MRAs at discharge after ACS. 20,21 This fact contrasts with the high use of other evidence-based post-myocardial infarction medications and identifies a specific gap in the translation of evidence into clinical practice. 22 However, the EPHESUS trial was conducted in patients receiving less effective therapy than the current standard of care, this trial enrolled more than 50% myocardial infarction patients without reperfusion therapy or revascularization 8 and as was suggested by Bossard et al contemporary data regarding the efficacy of MRAs are urgently needed, 22 including also patients without HF.…”

Mineralocorticoid receptor antagonists for heart failure: a real‐life observational study

“…It is also recognized that very few patients received eplerenone owing to the only recent commercial availability of this drug in Italy so that our results should not be extended to this specific MRA. Moreover, we have not evaluated rehospitalization rates, a study endpoint that was reported significantly reduced in a few MRA trials 21, 22. Lastly, the results of this study can only be applicable to HFrEF patients, as the role of MRA in HF patients with preserved systolic function has not been addressed.…”

“…Moreover, we have not evaluated rehospitalization rates, a study endpoint that was reported significantly reduced in a few MRA trials. 21,22 Lastly, the results of this study can only be applicable to HFrEF patients, as the role of MRA in HF patients with preserved systolic function has not been addressed.…”